| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.91(B) |
| Last
Volume: |
21,280,549 |
Avg
Vol: |
11,944,728 |
| 52
Week Range: |
$44.7 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
| Total People Sold |
0 |
0 |
3 |
6 |
| Total Sell Transactions |
0 |
0 |
3 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
19,501 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,074 |
18,953 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-03-10 |
4 |
D |
$68.42 |
$2,363,569 |
D/D |
(34,545) |
71,498 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,417 |
94,282 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,715 |
81,649 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,399 |
49,270 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
D |
$68.42 |
$3,072,126 |
D/D |
(44,901) |
373,627 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,288 |
403,642 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,273 |
388,747 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-03-10 |
4 |
D |
$68.42 |
$10,871,254 |
D/D |
(158,890) |
606,524 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
72,458 |
712,285 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
239,501 |
653,392 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-03-01 |
4 |
D |
$68.63 |
$707,095 |
D/D |
(10,303) |
69,284 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,350 |
79,587 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-03-01 |
4 |
D |
$68.63 |
$712,448 |
D/D |
(10,381) |
121,653 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,577 |
132,034 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-02-24 |
4 |
S |
$67.00 |
$2,010,000 |
D/D |
(30,000) |
453,455 |
|
-14% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-02-04 |
4 |
D |
$64.99 |
$85,267 |
D/D |
(1,312) |
56,237 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,593 |
57,549 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2021-12-31 |
4 |
D |
$62.35 |
$1,511,738 |
D/D |
(24,246) |
107,457 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,401 |
131,703 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
D |
$62.35 |
$1,436,108 |
D/D |
(23,033) |
53,956 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,029 |
76,989 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-12-16 |
4 |
S |
$61.99 |
$1,196,252 |
D/D |
(19,298) |
31,960 |
|
-24% |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2021-12-02 |
4 |
D |
$55.41 |
$249,234 |
D/D |
(4,498) |
84,302 |
|
- |
|
2225 Records found
|
|
Page 7 of 89 |
|
|
0.15 (0.34%) 
